Clinical Trial Update: Study Evaluating Bazedoxifene Dose-Response in Japanese Patients With Postmenopausal Osteoporosis. [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the dose-response of bazedoxifene in Japanese patients with postmenopausal osteoporosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Bazedoxifene (bazedoxifene)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Postmenopausal Osteoporosis | Phase 2 | Status: COMPLETED